Trikafta’s Approval the Outcome of ‘20-year Journey That Started with a Dream’, Says Vertex CEO Jeffrey Leiden
When Vertex Pharmaceuticals’ cystic fibrosis (CF) therapy Trikafta was approved recently by the U.S. Food and Drug Administration, it was a dream come true for Jeffrey Leiden, Vertex’s chairman, president, and CEO. The therapy, which treats the most common mutation in CF patients (the F508del mutation in…